INSIGHTS ON CELL & GENE THERAPY LOGISTICS

• Ever Wonder What Running A $50B Capital Facilities Project Feels Like?

  Eli Lilly and Company's projects in the U.S. include greenfield sites where little infrastructure exists. Here's how the company's approaching the challenge.

• BioRepository Services

  Reliable sample protection comes from secure facilities. Learn how multiple storage formats, split‑site options, and full audit trails help ensure biological materials remain ready for future use.

• Compliance, Costs, And Site Readiness In CAR-T Clinical Trials

  Navigate CAR-T trial complexity: uncover key compliance, budgeting, and site readiness strategies to ensure safe, efficient, and successful patient care.

• Managing Operational Challenges In CAR-T Clinical Trial Logistics

  Coordinating CAR-T trials means managing tight timelines, cryogenic handling, staffing gaps, and chain-of-identity risks where even small missteps can delay care.

• How To Select The Right Fill-Finish CDMO For Phase I–II

  Early‑phase programs require flexible, technically aligned fill‑finish partners. Mid‑sized CDMOs offer a balance of agility, infrastructure, and regulatory maturity suited to Phase I–II needs.

• Scientific Staffing

  A customizable scientific‑insourcing model delivers flexible onsite staffing, boosts lab capacity, reduces hiring burdens, and supports routine scientific work with trained professionals.

• Technical Field Services

  A flexible technical field‑services program offers multi‑vendor laboratory instrument support, facility services, relocations, and environmental qualifications to optimize operations, reduce risk, and maintain compliance.

• Defragmenting The Pre‑Clinical Supply Chain

  Fragmented pre‑clinical supply chains create avoidable delays and risks; unifying cryopreservation, logistics, and storage early improves consistency, reduces operational gaps, and supports smoother progression into clinical phases.

• Investors Trust Strong Supply Chains

  Investors now value operational maturity as much as science. Early, intentional supply‑chain planning shows scalability, lowers risk, and builds confidence in reliable growth.

• Green Supply Chains Rarely Start With A Pledge; Target Waste Instead

  Effective sustainability strategies in pharma supply chains reduce rework and overage. Three leakage points offer the most practical starting point for rooting out waste.